RDY - Dr. Reddy’s Laboratories Ltd ADR logo

Dr. Reddy’s Laboratories Ltd ADR

RDY

Dr. Reddy's Laboratories manufactures and markets a wide range of prescription and over-the-counter pharmaceuticals, including generics and active pharmaceutical ingredients. It serves various therapeutic areas, focusing on oncology, cardiovascular, and diabetes care.

⚕️ Healthcare NYSE Listed 2001 ₹ INR
$1,000 invested 1 year ago →$929today

Score Overview

1 Year
Score
Net Growth-26.44%
Net TrendShrank
Net Income Consistency—
Rev Growth-5.84%
Rev TrendShrank
Revenue Consistency—
5 Years
Score6.6
Net Growth40.73%
Net Trend60%
Net Income Consistency—
Rev Growth55.25%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth175.49%
Net Trend63%
Net Income Consistency
Rev Growth136.37%
Rev Trend80%
Revenue Consistency
20 Years
Score6.0
Net Growth254.76%
Net Trend61%
Net Income Consistency
Rev Growth410.10%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth6x
Net Trend57%
Net Income Consistency
Rev Growth20x
Rev Trend80%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Dr. Reddy’s Laboratories Ltd ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. RDY does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 12.85—
1 Year2025-09-29
$ 13.83-7.09%
5 Years2021-09-29
$ 11.4612.11%
10 Years2016-09-29
$ 7.4771.96%
20 Years2006-09-29
$ 2.36443.62%
All Time2001-04-11
$ 0.7217x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in INR

Year
TTM₹ 332.83B₹ 33.16B₹ 81.42B
2026₹ 353.47B₹ 45.08B₹ 86.07B
2025₹ 325.53B₹ 56.54B₹ 57.90B
2024₹ 279.16B₹ 55.68B₹ 81.47B
2023₹ 245.87B₹ 45.06B₹ 61.79B
2022₹ 214.39B₹ 23.56B₹ 44.36B
2021₹ 2.55B₹ 472M
2020₹ 174.60B₹ 19.49B₹ 340M
2019₹ 153.85B₹ 18.79B₹ 24.75B
2018₹ 142.02B₹ 9.80B₹ 20.96B
2017₹ 140.80B₹ 12.03B₹ 18.13B
2016₹ 154.70B₹ 20.01B₹ 39.95B
2015₹ 148.18B₹ 22.17B₹ 39.65B
2014₹ 132.17B₹ 21.51B₹ 33.53B
2013₹ 116.26B₹ 16.77B₹ 220.99B
2012₹ 96.73B₹ 14.26B₹ 18.15B
2011₹ 74.69B₹ 11.04B₹ 5.76B
2010₹ 70.27B₹ 1.06B₹ 10.75B
2009₹ 69.44B-₹ 5.16B₹ 6.12B
2008₹ 50.00B₹ 4.67B₹ 12.15B
2007₹ 65.24B₹ 9.34B₹ 18.03B
2006₹ 24.32B₹ 1.63B
2005₹ 19.47B₹ 211M₹ 9.59B
2004₹ 20.12B₹ 2.47B₹ 6.92B
2003₹ 18.01B₹ 3.52B₹ 7.25B
2002₹ 16.60B₹ 4.91B₹ 5.10B
RDY - Dr. Reddy’s Laboratories Ltd ADR logo

Dr. Reddy’s Laboratories Ltd ADR fundamental performance

Between 2021 and 2026, revenue grew from ₹ 2.55B to ₹ 353.47B. Revenue increased in 4 of those 5 years; net income in 3.

Across Dr. Reddy’s Laboratories Ltd ADR's full reported history, from 2002 to 2026, revenue grew from ₹ 16.60B to ₹ 353.47B and net income grew from ₹ 4.91B to ₹ 45.08B. Revenue increased in 80% of the years measured; net income in 57%.

Dr. Reddy’s Laboratories Ltd ADR currently holds a 20-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.

Membership

Explore RDY with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies